Latest & greatest articles for adhd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adhd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adhd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

ADHD

ADHD (or Attention deficit hyperactivity disorder) is a neurodevelopmental type mental disorder. It is characterised two main categories of two types of behavioural problems:

  • inattentiveness
  • hyperactivity and impulsiveness

Most people with ADHD have problems that fall into both categories, but it doesn’t have to be the case. If a person just has inattentiveness it is referred to as attention deficit disorder (ADD).

Methylphenidate is a commonly used medication used to treat patients suffering from attention-deficit hyperactivity disorder. Methylphenidate is part of a group of drugs known as stimulants. Central nervous system stimulants help change the amounts of natural substances in the brain. But it is not the only intervention; others include Bupropion, exercise and CBT (Cognitive behavioural therapy).

Extensive ADHD research and case studies have been carried out over numerous years. Trip has unrivalled coverage of the evidence base including systematic reviews, clinical trials, clinical guidelines and case studies.

Studies are ongoing to assess the safety and effectiveness of stimulants used on children with ADHD and intellectual disabilities as well as in other populations and other interventions. Trip also includes ongoing controlled trials and ongoing systematic reviews (via the PROSPERO database).

Top results for adhd

41. Attention deficit hyperactivity disorder (ADHD): avoid guanfacine

hyperactivity disorder (ADHD): avoid guanfacine In children diagnosed with attention deficit hyperactivity disorder (ADHD), guanfacine has no proven efficacy in improving family and social relationships. On the other hand, it has frequent, sometimes severe, adverse effects. In practice, it is best to avoid guanfacine. The diagnosis of attention deficit hyperactivity disorder in children is based on non-specific behavioural symptoms: inattentiveness, hyperactivity and impulsiveness. The disruptive impact (...) Attention deficit hyperactivity disorder (ADHD): avoid guanfacine Prescrire IN ENGLISH - Spotlight ''Attention deficit hyperactivity disorder (ADHD): avoid guanfacine'', 1 October 2017 {1} {1} {1} | | > > > Attention deficit hyperactivity disorder (ADHD): avoid guanfacine Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Attention deficit

2017 Prescrire

42. Attentin (dexamfetamine) - attention deficit/hyperactivity disorder (ADHD)

Attentin (dexamfetamine) - attention deficit/hyperactivity disorder (ADHD) Attentin (dexamfetamine) × Insert searchphrase to search the website Insert searchphrase to search the website > > > Attentin (dexamfetamine) Conclusion Attentin (dexamfetamine) is a CNS stimulant agent for treatment of attention deficit/hyperactivity disorder (ADHD) in children and adolescents aged 6-17 years. Attentin can be used second-line when response to methylphenidate is not sufficiently effective or has caused (...) unacceptable adverse reactions. The indication for medicinal treatment of ADHD is made by a specialist in child and adolescent psychiatry upon which further treatment (maintenance treatment) may be decided by the general practitioner in collaboration with a child and adolescent psychiatrist (1). Pharmaceutical treatment should not be the only treatment for ADHD, but should be combined with non-pharmaceutical interventions (1). The effect of dexamfetamine on ADHD core symptoms in children and adults has

2017 Danish Pharmacotherapy Reviews

43. Intuniv (guanfacine) - ADHD

Intuniv (guanfacine) - ADHD Intuniv® (guanfacine) × Insert searchphrase to search the website Insert searchphrase to search the website > > > Intuniv® (guanfacine) Conclusion With Intuniv (guanfacine), a new type of non-stimulant ADHD medication is introduced. Intuniv is approved for the treatment of ADHD in children and adolescents when central nervous stimulants are not suitable, not tolerated or have no effect. Thus, Intuniv has a more restrictive indication compared to the other non (...) -stimulant ADHD medicine, atomoxetine. Compared to placebo, Intuniv has an effect on ADHD core symptoms with medium effect size. It suggests that the effect of Intuniv is lower than that of methylphenidate, but comparable to or higher than that of atomoxetine. No convincing effect on functioning has been established. Adverse reactions and risks of interactions are significant and may be serious; especially sedation and somnolence are common and influence Intuniv's effect on ADHD core symptoms. Intuniv

2017 Danish Pharmacotherapy Reviews

44. ADHD Medication and Substance-Related Problems Full Text available with Trip Pro

ADHD Medication and Substance-Related Problems Substance use disorders are major contributors to excess mortality among individuals with attention deficit hyperactivity disorder (ADHD), yet associations between pharmacological ADHD treatment and substance-related problems remain unclear. This study investigated concurrent and long-term associations between ADHD medication treatment and substance-related events.The authors analyzed 2005-2014 commercial health care claims from 2,993,887 (47.2 (...) % female) adolescent and adult ADHD patients. Within-individual analyses compared the risk of substance-related events (i.e., emergency department visits related to substance use disorders) during months in which patients received prescribed stimulant medication or atomoxetine relative to the risk during months in which they did not.In adjusted within-individual comparisons, relative to periods in which patients did not receive ADHD medication, male patients had 35% lower odds of concurrent substance

2017 EvidenceUpdates

45. The Assessment and Treatment of Adult Inmates with Attention Deficit Hyperactivity Disorder: Clinical Effectiveness and Guidelines

. Tags mental health, attention deficit disorder with hyperactivity, criminals, prisoners, prisons, ADHD, inmate, prisoner, hyperactive, Hyperactivity, ADD, correctional Files Rapid Response Reference List Published : June 20, 2017 Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get our newsletter: (...) The Assessment and Treatment of Adult Inmates with Attention Deficit Hyperactivity Disorder: Clinical Effectiveness and Guidelines The Assessment and Treatment of Adult Inmates with Attention Deficit Hyperactivity Disorder: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need The Assessment and Treatment of Adult Inmates with Attention Deficit Hyperactivity Disorder: Clinical Effectiveness and Guidelines The Assessment and Treatment of Adult Inmates with Attention

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

46. Prenatal antidepressant use and risk of attention-deficit/hyperactivity disorder in offspring: population based cohort study. Full Text available with Trip Pro

Prenatal antidepressant use and risk of attention-deficit/hyperactivity disorder in offspring: population based cohort study. Objective To assess the potential association between prenatal use of antidepressants and the risk of attention-deficit/hyperactivity disorder (ADHD) in offspring.Design Population based cohort study.Setting Data from the Hong Kong population based electronic medical records on the Clinical Data Analysis and Reporting System.Participants 190 618 children born in Hong (...) use during pregnancy was 2.26 (P<0.01) compared with non-use. After adjustment for potential confounding factors, including maternal psychiatric disorders and use of other psychiatric drugs, the adjusted hazard ratio was reduced to 1.39 (95% confidence interval 1.07 to 1.82, P=0.01). Likewise, similar results were observed when comparing children of mothers who had used antidepressants before pregnancy with those who were never users (1.76, 1.36 to 2.30, P<0.01). The risk of ADHD in the children

2017 BMJ

47. Effectiveness of methylphenidate and PUFA for the treatment of patients with ADHD: A double-blinded randomized clinical trial Full Text available with Trip Pro

Effectiveness of methylphenidate and PUFA for the treatment of patients with ADHD: A double-blinded randomized clinical trial In some children with ADHD, sub-optimal levels of various nutrients including PUFA especially omega-3 has been observed, and contradictory reports exist on the results of studies conducted on the positive therapeutic effects of PUFA in patients with ADHD.The aim of this study was to investigate the effectiveness of methylphenidate and PUFA on treatment of patients (...) with ADHD in Zahedan, Iran.In this clinical trial, 40 children between 6 and 12 years of age with ADHD were investigated in Zahedan in 2014. Patients were randomly divided into two groups of methylphenidate plus PUFA and methylphenidate plus placebo. ADHD rating scale was filled before and after the study for patients of both groups. Finally, data were analyzed using SPSS18, paired-samples t-test and chi-square.Mean age of patients was 2.9±1.8 years. Thirty-three children (82.5%) were boys and seven

2017 Electronic physician Controlled trial quality: uncertain

48. Smoking, alcohol and drug use in youth and adults with attention-deficit hyperactivity disorder Full Text available with Trip Pro

Smoking, alcohol and drug use in youth and adults with attention-deficit hyperactivity disorder Previous research suggests a relationship between attention-deficit hyperactivity disorder (ADHD) and smoking, alcohol and illicit drug use, however most studies have focused on adolescents or young adults, or clinically ascertained samples.To analyse population-based data on the relationship between ADHD and at-risk health behaviours in adolescents and adults.Data were derived from a Statistics (...) Canada population-based health survey. The association between the diagnosis of ADHD and smoking, alcohol use, and illicit drug use was examined.Individuals with ADHD started smoking at a younger age. They consumed more alcoholic drinks on drinking days, and women with ADHD were more likely to engage in binge drinking. Women over the age of 25 and men with ADHD were more likely to meet alcohol-dependence lifetime criteria. People with ADHD were at a greater risk of drug misuse and dependence.People

2017 BJPsych open

49. Occupational therapy for attention-deficit/hyperactivity disorder (ADHD)

Occupational therapy for attention-deficit/hyperactivity disorder (ADHD) Occupational therapy for attention-deficit/hyperactivity disorder (ADHD) Occupational therapy for attention-deficit/hyperactivity disorder (ADHD) HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Occupational therapy for attention-deficit/hyperactivity disorder (ADHD (...) ) Lansdale: HAYES, Inc. Directory Publication. 2017 Authors' conclusions Occupational therapy (OT) for attention-deficit/hyperactivity disorder (ADHD) encompasses a wide array of interventions, with the aim of increasing function in all aspects of life and settings (school, home, etc.). Specific interventions vary and are determined by the occupational therapist depending on the presenting problems, deficits, and the therapist's determination of the best course of treatment. OT interventions for ADHD can

2017 Health Technology Assessment (HTA) Database.

50. Associations of Maternal Antidepressant Use During the First Trimester of Pregnancy With Preterm Birth, Small for Gestational Age, Autism Spectrum Disorder, and Attention-Deficit/Hyperactivity Disorder in Offspring. Full Text available with Trip Pro

Associations of Maternal Antidepressant Use During the First Trimester of Pregnancy With Preterm Birth, Small for Gestational Age, Autism Spectrum Disorder, and Attention-Deficit/Hyperactivity Disorder in Offspring. Prenatal antidepressant exposure has been associated with adverse outcomes. Previous studies, however, may not have adequately accounted for confounding.To evaluate alternative hypotheses for associations between first-trimester antidepressant exposure and birth (...) weeks), small for gestational age (birth weight <2 SDs below the mean for gestational age), and first inpatient or outpatient clinical diagnosis of autism spectrum disorder and attention-deficit/hyperactivity disorder in offspring.Among 1 580 629 offspring (mean gestational age, 279 days; 48.6% female; 1.4% [n = 22 544] with maternal first-trimester self-reported antidepressant use) born to 943 776 mothers (mean age at childbirth, 30 years), 6.98% of exposed vs 4.78% of unexposed offspring were

2017 JAMA

51. Reward-related ventral striatum activity links polygenic risk for attention-deficit/hyperactivity disorder to problematic alcohol use in young adulthood Full Text available with Trip Pro

Reward-related ventral striatum activity links polygenic risk for attention-deficit/hyperactivity disorder to problematic alcohol use in young adulthood Problematic alcohol use in adolescence and adulthood is a common and often debilitating correlate of childhood attention-deficit/hyperactivity disorder (ADHD). Converging evidence suggests that ADHD and problematic alcohol use share a common additive genetic basis, which may be mechanistically related to reward-related brain function (...) . In the current study, we examined whether polygenic risk for childhood ADHD is linked to problematic alcohol use in young adulthood through alterations in reward-related activity of the ventral striatum, a neural hub supporting appetitive behaviors and reinforcement learning.Genomic, neuroimaging, and self-report data were available for 404 non-Hispanic European-American participants who completed the ongoing Duke Neurogenetics Study. Polygenic risk scores for childhood ADHD were calculated based on a genome

2017 Biological psychiatry. Cognitive neuroscience and neuroimaging

52. The Cochrane Collaboration withdraws a review on methylphenidate for adults with attention deficit hyperactivity disorder

The Cochrane Collaboration withdraws a review on methylphenidate for adults with attention deficit hyperactivity disorder Kim Boesen , Luis Carlos Saiz , Juan Erviti , Ole Jakob Storebø , Christian Gluud , Peter C Gøtzsche , Karsten Juhl Jørgensen Statistics from Altmetric.com Background Attention deficit hyperactivity disorder (ADHD) in adults is one of the most controversial diagnoses in medicine, and the use of methylphenidate is sharply rising. The Cochrane review by Epstein and colleagues about (...) The trials lasted only 1–7 weeks, and the long-term beneficial and harmful effects of methylphenidate are therefore unknown. Most adults with ADHD receive methylphenidate for substantially longer periods, and the beneficial effects may furthermore diminish over time. This was observed in the large Multimodal Treatment of Attention Deficit Hyperactivity Disorder Study in children. The short trial duration should therefore have led to additional downgrading for indirectness according to GRADE. Small trials

2017 Evidence-Based Medicine

53. Causes and risk factors: Childhood comorbidity and parental mental health problems appear to be associated with ADHD persistence

factors Childhood comorbidity and parental mental health problems appear to be associated with ADHD persistence Jessica Agnew-Blais King's College London, London, UK; jessica.agnew-blais{at}kcl.ac.uk Statistics from Altmetric.com ABSTRACT FROM: Roy A, Hechtman L, Arnold LE, et al . Childhood factors affecting persistence and desistence of attention-deficit/hyperactivity disorder symptoms in adulthood: results from the MTA. J Am Acad Child Adolesc Psychiatry 2016;55:937–44. What is already known (...) on this topic While many children with attention-deficit hyperactivity disorder (ADHD) will experience remission of the disorder, 1 a substantial proportion will continue to have ADHD and associated impairments into adolescence and adulthood. 2 Those with persistent ADHD have poorer outcomes later in life in some domains, including more emotional and substance use problems, compared to those whose ADHD remits. 3 Previous studies have identified factors such as childhood ADHD severity, comorbidities 4 and IQ

2017 Evidence-Based Mental Health

54. Pharmacological and non-pharmacological treatment of adults with ADHD: a meta-review

Crescenzo , Samuele Cortese , , Nicoletta Adamo , Luigi Janiri Statistics from Altmetric.com Introduction Attention-deficit/hyperactivity disorder (ADHD) is one of the most common neuropsychiatric conditions, with a pooled worldwide prevalence estimated at about 5% in school-aged children and persistence of impairing symptoms in adulthood in up to 65% of cases. The pooled estimated prevalence of ADHD (as categorical diagnosis) in adults is around 2.5%. ADHD is characterised by a persistent and impairing (...) value of combining pharmacological and non-pharmacological treatments. References Faraone SV , Asherson P , Banaschewski T , et al . Attention-deficit/hyperactivity disorder . Moffitt TE , Houts R , Asherson P , et al . Is adult ADHD a childhood-onset neurodevelopmental disorder? Evidence from a four-decade longitudinal cohort study . Seixas M , Weiss M , Muller U . Systematic review of national and international guidelines on attention-deficit hyperactivity disorder . Thapar A , Cooper M

2017 Evidence-Based Mental Health

55. Medications for attention deficit hyperactivity disorder (ADHD) in children

Medications for attention deficit hyperactivity disorder (ADHD) in children

2017 DynaMed Plus

57. Attention deficit hyperactivity disorder (ADHD) in children and adolescents

Attention deficit hyperactivity disorder (ADHD) in children and adolescents

2017 DynaMed Plus

59. Vitamin levels in adults with ADHD Full Text available with Trip Pro

Vitamin levels in adults with ADHD Micronutrients containing vitamins are reported to reduce symptom levels in persons with attention-deficit hyperactivity disorder (ADHD), but data on vitamin levels in ADHD are sparse.To examine the relationship between vitamin concentrations, ADHD diagnosis and psychiatric symptoms in young adult ADHD patients and controls.Eight vitamins and the nicotine metabolite cotinine were analysed in serum samples from 133 ADHD patients and 131 controls aged between 18 (...) and 40, who also reported ADHD symptoms and comorbid conditions.Lower concentrations of vitamins B2, B6 and B9 were associated with the ADHD diagnosis, and B2 and B6 also with symptom severity. Smokers had lower levels of vitamins B2 and B9.ADHD patients were overrepresented in the group with low levels of some vitamins, possibly indicative of inadequate dietary intake of these micronutrients in a subgroup of patients. It is important to identify these patients in dietary intervention trials

2016 BJPsych open

60. Practice advisory: The utility of EEG theta/beta power ratio in ADHD diagnosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology Full Text available with Trip Pro

Practice advisory: The utility of EEG theta/beta power ratio in ADHD diagnosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology To evaluate the evidence for EEG theta/beta power ratio for diagnosing, or helping to diagnose, attention-deficit/hyperactivity disorder (ADHD).We identified relevant studies and classified them using American Academy of Neurology criteria.Two Class I studies assessing the ability of EEG theta (...) /beta power ratio and EEG frontal beta power to identify patients with ADHD correctly identified 166 of 185 participants. Both studies evaluated theta/beta power ratio and frontal beta power in suspected ADHD or in syndromes typically included in an ADHD differential diagnosis. A bivariate model combining the diagnostic studies shows that the combination of EEG frontal beta power and theta/beta power ratio has relatively high sensitivity and specificity but is insufficiently accurate.It is unknown

2016 EvidenceUpdates